Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients
Authors
Millán-Esteban, D.García-Casado, Z.
Manrique-Silva, E.
Virós, Amaya
Kumar, R.
Furney, S.
López-Guerrero, J. A.
Requena, C.
Bañuls, J.
Traves, V.
Nagore, E.
Affiliation
Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, València, Spain.Issue Date
2021
Metadata
Show full item recordAbstract
Background: KIT mutations are primarily associated with acral and mucosal melanoma, and have been reported to show higher prevalence in chronic sun-damaged (CSD) than non-CSD melanomas. Objectives: To investigate the prevalence of KIT mutations in melanoma according to subtype, and determine the clinical role of such mutations. Material & methods: We present results from a study of a Spanish population of 492 melanomas, classified according to the latest World Health Organization (WHO) guidelines. We analysed the mutational status of KIT and correlated with different clinical variables related to sun exposure and family history. Results: KIT mutations were significantly more frequent in acral (3/36; 8.3%) and mucosal (4/8; 50%) melanomas than non-acral cutaneous melanomas. No significant difference was observed in KIT mutational status between CSD and non-CSD melanomas. Conclusion: Our results suggest that KIT mutations in melanoma tumours are unrelated to the development of nevi or chronic sun damage, but their presence is associated with aggressive melanomas which show ulceration, vascular invasiveness, and increased Breslow thickness. These findings are consistent with those reported by The Cancer Genome Atlas network.Citation
Millan-Esteban D, Garcia-Casado Z, Manrique-Silva E, Viros A, Kumar R, Furney S, et al. Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients. Eur J Dermatol. 2021.Journal
European Journal of DermatologyDOI
10.1684/ejd.2021.3971PubMed ID
33648909Additional Links
https://dx.doi.org/10.1684/ejd.2021.3971Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1684/ejd.2021.3971
Scopus Count
Collections
Related articles
- The clinical significance of KIT mutations in melanoma: a meta-analysis.
- Authors: Gong HZ, Zheng HY, Li J
- Issue date: 2018 Aug
- Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
- Authors: Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A, Dobrovic A, Kelly J, McArthur GA
- Issue date: 2010 Apr
- Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
- Authors: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE
- Issue date: 2013 Sep 10
- GAB2 amplifications refine molecular classification of melanoma.
- Authors: Chernoff KA, Bordone L, Horst B, Simon K, Twadell W, Lee K, Cohen JA, Wang S, Silvers DN, Brunner G, Celebi JT
- Issue date: 2009 Jul 1
- KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
- Authors: Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH, Kim KM
- Issue date: 2011 Jun